07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Intra-anal nifedipine: Phase III started

RDD Pharma began a double-blind, placebo-controlled, European Phase III trial to evaluate 12 mg intra-anal nifedipine once or twice daily for 8 weeks in about 470 patients. The company is developing RDD-1219 under section 505(b)(2)...
08:00 , Dec 22, 2014 |  BioCentury  |  Regulation

Drug price changes loom in China

Already facing a long runway to get innovative drugs on the market in China, multinational pharma companies will see their "independent pricing" power removed on mature drugs under sweeping reforms the government is expected to...
08:00 , Jan 4, 2010 |  BioCentury  |  Tools & Techniques

Celling cardiotox in a dish

Cellular Dynamics International Inc. has overcome a technical hurdle that has until now prevented the use of stem cell technologies to develop high throughput cell-based screens for preclinical toxicity studies. The company believes its iCell...
07:00 , Aug 6, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Cognitive dysfunction Calcium channel L-type In vitro and rat studies suggest that agonizing L-type voltage-dependent calcium channels could help enhance memory and treat cognitive dysfunction....
07:00 , Oct 1, 2007 |  BC Week In Review  |  Clinical News

Adalat GITS nifedipine: Phase IV started

BAY's Bayer Schering Pharma AG unit began the double-blind, European Phase IV TALENT trial in 400 patients to evaluate Adalat GITS nifedipine in combination with Pritor telmisartan, an angiotensin II receptor (type AT1) antagonist. BAY,...
07:00 , Oct 1, 2007 |  BC Week In Review  |  Clinical News

Micardis telmisartan: Phase IV started

BAY's Bayer Schering Pharma AG unit began the double-blind, European Phase IV TALENT trial in 400 patients to evaluate Adalat GITS nifedipine in combination with Pritor telmisartan, an angiotensin II receptor (type AT1) antagonist. BAY,...
08:00 , Feb 19, 2007 |  BC Week In Review  |  Clinical News

Bayer preclinical data

In a murine model of hemochromatosis, nifedipine helped mobilize iron from stores in the liver and enhanced urinary iron excretion. Nifedipine is a L-type calcium channel blocker. Data were published in Nature Medicine. Bayer AG...
08:00 , Mar 28, 2005 |  BC Week In Review  |  Clinical News

Adalat GITS nifedipine cardiovascular data

Data from a prospectively defined subgroup analysis of 7,665 patients from the ACTION study showed that the addition of Adalat GITS nifedipine to existing therapy led to a 13% reduction in the combined rate of...
08:00 , Jan 3, 2005 |  BioCentury  |  Strategy

Elan chronicles

Elan chronicles...
07:00 , Sep 20, 2004 |  BC Week In Review  |  Company News

Bayer, Schering-Plough deal

SGP acquired exclusive rights to market, sell and distribute in the U.S. and Puerto Rico certain primary healthcare products from Bayer Healthcare, a unit of BAYG. The products include antibiotics Avelox moxifloxacin and Cipro ciprofloxacin,...